In a recent study, the topical phosphodiesterase 4 inhibitor PF-07038124 exhibited promising results in treating mild to moderate atopic dermatitis (AD) and plaque psoriasis. The trial included 104 patients, with PF-07038124 groups showing significantly greater improvements in EASI and PASI scores at week six compared to the vehicle groups. Importantly, PF-07038124 demonstrated superior efficacy without application site reactions, making it a well-tolerated treatment option for these inflammatory skin diseases. The findings highlight the potential of PF-07038124 in addressing the unmet need for effective topical treatments in AD and plaque psoriasis.
Like
Save
Share